BRPI0418552A - compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas - Google Patents
compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinasInfo
- Publication number
- BRPI0418552A BRPI0418552A BRPI0418552-8A BRPI0418552A BRPI0418552A BR PI0418552 A BRPI0418552 A BR PI0418552A BR PI0418552 A BRPI0418552 A BR PI0418552A BR PI0418552 A BRPI0418552 A BR PI0418552A
- Authority
- BR
- Brazil
- Prior art keywords
- integrins
- piperidinyl
- selectively bind
- targeting compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"COMPOSTO DE ALVEJAMENTO DE PIPERIDINILA QUE SELETIVAMENTE LIGAM-SE à INTEGRINAS". A presente invenção refere-se à síntese e aplicação biológica de porção de afinidade de antagonistas de integrina de ácido carboxílico de piperidinoíla da Fórmula (I) e Fórmula (II). Estas porções de afinidade podem ser empregadas com lipossomas ou agentes de imageamento para alvejar células que expressam os receptores de integrina <244> v~ <244> 3~ <244> v~ <244> 5~, ou <244> v~ <244> 6~.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/782,060 US20040224986A1 (en) | 2002-08-16 | 2004-02-18 | Piperidinyl targeting compounds that selectively bind integrins |
PCT/US2004/009465 WO2005082889A1 (en) | 2004-02-18 | 2004-03-29 | Piperidinyl targeting compounds that selectively bind integrins |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0418552A true BRPI0418552A (pt) | 2007-05-22 |
Family
ID=34911385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0418552-8A BRPI0418552A (pt) | 2004-02-18 | 2004-03-29 | compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas |
Country Status (19)
Country | Link |
---|---|
US (3) | US20040224986A1 (pt) |
EP (1) | EP1718635A1 (pt) |
JP (1) | JP2007523907A (pt) |
KR (1) | KR20070010125A (pt) |
CN (1) | CN101023072A (pt) |
AU (1) | AU2004316476A1 (pt) |
BR (1) | BRPI0418552A (pt) |
CA (1) | CA2556768A1 (pt) |
EA (1) | EA200601517A1 (pt) |
EC (1) | ECSP066778A (pt) |
HR (1) | HRP20060298A2 (pt) |
IL (1) | IL177502A0 (pt) |
IS (1) | IS8532A (pt) |
ME (1) | MEP48908A (pt) |
MX (1) | MXPA06009503A (pt) |
NO (1) | NO20064212L (pt) |
RS (1) | RS20060470A (pt) |
WO (1) | WO2005082889A1 (pt) |
ZA (1) | ZA200607756B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
EP1940841B9 (fr) | 2005-10-07 | 2017-04-19 | Guerbet | Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
JP2011519340A (ja) * | 2007-10-30 | 2011-07-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換アルカン酸調製のためのエナンチオ選択的プロセスこの米国特許正規出願は、2007年10月30日に提出された米国特許仮出願第61/001,004号、及び2008年2月29日に提出された米国特許仮出願第61/067,842号の権利を主張する。 |
EP2268317B1 (en) | 2008-03-14 | 2020-02-26 | VisEn Medical, Inc. | Integrin targeting agents and in vivo and in vitro imaging methods using the same |
ES2445199T3 (es) | 2008-06-05 | 2014-02-28 | Glaxo Group Limited | Derivados de benzpirazol como inhibidores de PI3-quinasas |
EP2280705B1 (en) | 2008-06-05 | 2014-10-08 | Glaxo Group Limited | Novel compounds |
WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
EP2406255B1 (en) | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
CA2759476C (en) | 2009-04-30 | 2018-10-09 | Julie Nicole Hamblin | Novel compounds |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
PT3050878T (pt) | 2013-09-24 | 2021-12-02 | Fujifilm Corp | Novo composto contendo azoto ou seu sal, ou seu complexo de metal |
GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417002D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201604681D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
CN112074290B (zh) * | 2018-04-27 | 2024-09-10 | 箭头药业股份有限公司 | 整联蛋白靶向配体和其用途 |
CR20230472A (es) * | 2021-03-10 | 2024-03-21 | Dice Molecules Sv Inc | Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN148482B (pt) * | 1977-06-03 | 1981-03-07 | Pfizer | |
EP1306095A3 (en) * | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
US5902795A (en) * | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
US5340798A (en) * | 1992-10-14 | 1994-08-23 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5753659A (en) * | 1993-03-29 | 1998-05-19 | Zeneca Limited | Heterocyclic compouds |
JPH10506560A (ja) | 1995-04-19 | 1998-06-30 | シュナイダー(ユーエスエー)インク | 薬品を放出する被覆されたステント |
DE19613933A1 (de) | 1996-04-06 | 1997-10-09 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US5919792A (en) * | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
AU5596298A (en) | 1996-12-09 | 1998-07-03 | Cor Therapeutics, Inc. | Integrin antagonists |
DZ2609A1 (fr) | 1997-09-19 | 2003-03-01 | Smithkline Beecham Corp | Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant. |
US6211191B1 (en) * | 1997-12-17 | 2001-04-03 | Merck & Co., Inc. | Integrin receptor antagonists |
TR200002557T2 (tr) | 1997-12-17 | 2000-12-21 | Merck & Co., Inc. | İntegrin reseptörü antagonistleri |
EA200001007A1 (ru) | 1998-03-31 | 2001-04-23 | Дюпон Фармасьютикалз Компани | Фармацевтические препараты для визуализации ангиогенных расстройств |
UA71586C2 (en) | 1998-12-04 | 2004-12-15 | Smithkline Beecham Corp | A vitronectin receptor antagonist |
US6511648B2 (en) | 1998-12-18 | 2003-01-28 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
DK1140203T3 (da) | 1998-12-18 | 2007-09-10 | Bristol Myers Squibb Pharma Co | Farmaceutiske præparater som vitronectinreceptorantagonist |
CA2349333A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
JP2002537260A (ja) | 1999-02-17 | 2002-11-05 | メルク エンド カムパニー インコーポレーテッド | αVインテグリン受容体拮抗薬としてのジベンゾ−アゼピン誘導体 |
EP1185559A2 (en) * | 1999-04-28 | 2002-03-13 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
PT1187592E (pt) | 1999-06-02 | 2007-10-19 | Merck & Co Inc | Antagonistas dos receptores de integrina alfa v |
CA2352957A1 (en) | 1999-09-29 | 2001-04-05 | Ortho-Mcneil Pharmaceutical, Inc. | Isonipecotamides for the treatment of integrin-mediated disorders |
US6784291B2 (en) * | 2000-05-04 | 2004-08-31 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US7119098B2 (en) | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
US20040009465A1 (en) | 2002-07-12 | 2004-01-15 | Voraphat Luckanatinvong | Shelf life indicator components for fresh cut fruits and vegetables responding to carbondioxide |
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
DK1539739T3 (da) * | 2002-08-16 | 2011-03-07 | Janssen Pharmaceutica Nv | Piperidinylforbindelser, der selektivt binder integriner |
-
2004
- 2004-02-18 US US10/782,060 patent/US20040224986A1/en not_active Abandoned
- 2004-03-29 JP JP2006554073A patent/JP2007523907A/ja active Pending
- 2004-03-29 KR KR1020067019197A patent/KR20070010125A/ko not_active Application Discontinuation
- 2004-03-29 EP EP04749482A patent/EP1718635A1/en not_active Withdrawn
- 2004-03-29 AU AU2004316476A patent/AU2004316476A1/en not_active Abandoned
- 2004-03-29 EA EA200601517A patent/EA200601517A1/ru unknown
- 2004-03-29 ME MEP-489/08A patent/MEP48908A/xx unknown
- 2004-03-29 CA CA002556768A patent/CA2556768A1/en not_active Abandoned
- 2004-03-29 BR BRPI0418552-8A patent/BRPI0418552A/pt not_active IP Right Cessation
- 2004-03-29 RS YUP-2006/0470A patent/RS20060470A/sr unknown
- 2004-03-29 CN CNA2004800427641A patent/CN101023072A/zh active Pending
- 2004-03-29 MX MXPA06009503A patent/MXPA06009503A/es unknown
- 2004-03-29 WO PCT/US2004/009465 patent/WO2005082889A1/en active Application Filing
-
2006
- 2006-08-15 IL IL177502A patent/IL177502A0/en unknown
- 2006-08-17 IS IS8532A patent/IS8532A/is unknown
- 2006-08-18 EC EC2006006778A patent/ECSP066778A/es unknown
- 2006-09-13 HR HR20060298A patent/HRP20060298A2/xx not_active Application Discontinuation
- 2006-09-15 ZA ZA200607756A patent/ZA200607756B/en unknown
- 2006-09-18 NO NO20064212A patent/NO20064212L/no not_active Application Discontinuation
-
2007
- 2007-08-30 US US11/897,484 patent/US7879881B2/en not_active Expired - Fee Related
-
2010
- 2010-12-22 US US12/975,900 patent/US8110683B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HRP20060298A2 (en) | 2007-03-31 |
KR20070010125A (ko) | 2007-01-22 |
US20040224986A1 (en) | 2004-11-11 |
US8110683B2 (en) | 2012-02-07 |
US7879881B2 (en) | 2011-02-01 |
IL177502A0 (en) | 2006-12-10 |
IS8532A (is) | 2006-09-15 |
MEP48908A (en) | 2011-02-10 |
JP2007523907A (ja) | 2007-08-23 |
NO20064212L (no) | 2006-11-15 |
CA2556768A1 (en) | 2005-09-09 |
MXPA06009503A (es) | 2007-04-19 |
RS20060470A (en) | 2008-11-28 |
US20080058359A1 (en) | 2008-03-06 |
ZA200607756B (en) | 2008-06-25 |
US20110092528A1 (en) | 2011-04-21 |
WO2005082889A1 (en) | 2005-09-09 |
EP1718635A1 (en) | 2006-11-08 |
ECSP066778A (es) | 2006-11-16 |
EA200601517A1 (ru) | 2007-06-29 |
CN101023072A (zh) | 2007-08-22 |
AU2004316476A1 (en) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0418552A (pt) | compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas | |
MA29975B1 (fr) | Antagonistes de la neuropiline | |
DK1272507T3 (da) | Integrinbindende peptidderivater | |
WO2006090389A3 (en) | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof | |
UY26057A1 (es) | Amidas de aminoacidos modificadas, medicamentos que contienen estos compuestos y procedimiento para su preparacion | |
WO2005121778A3 (en) | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases | |
WO2004019878A3 (en) | Adzymes and uses thereof | |
MA29014B1 (fr) | Formulations d'anticorps | |
ATE485049T1 (de) | Physiologisch aktive zusammensetzung gegen diabetes | |
ATE484505T1 (de) | 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten | |
NO20073039L (no) | Kontrastmidler | |
UA87841C2 (ru) | Композиция, которая содержит амброксол, для местного применения | |
PL1765863T3 (pl) | Związki oparte na peptydach | |
BRPI0716491A2 (pt) | Composto sulfonamida ou sal do mesmo 3/00 c07c 311/21 c07c 311/29 c07d 207/27 c07d 207/325 c07d 209/08 c07d 213/40 c07d 213/68 c07d 213/70 c07d 213/79 c07d 213/89 c07d 215/12 c07d 217/06 c07d 231/12 c07d 237/08 c07d 239/26 c07d 241/12 c07d 249/08 c07d 263/32 c07d 263/58 c07d 277/20 c07d 277/28 c07d 277/36 c07d 295/12 c07d 307/52 c07d 307/81 c07d 333/20 c07d 333/34 c07d 333/38 c07d 333/40 c07d 333/58 c07k 7/00 | |
MX2007004277A (es) | Compuestos para la produccion de imagenes por perfusion miocardial. | |
DE60217854D1 (de) | Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung | |
HK1098077A1 (en) | Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin | |
ATE425770T1 (de) | Kontrastmittel | |
WO2004087734A3 (en) | Stq-peptides | |
BR0115440A (pt) | Antagonista de receptores de bombesina | |
WO2005093091A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26) | |
WO2005040825A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20) | |
WO2005040211A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1) | |
FR2887433B1 (fr) | Plaque d'osteotomie tibiale d'addition | |
DE602004014261D1 (de) | Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 3A, 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |